Victory Capital Management Inc Iveric Bio, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	SELL	$26.24 - $39.63 $8,921 - $13,474	-340 Reduced 2.28%	14,564 $572,000
Q1 2023 May 02, 2023	BUY	$18.67 - $24.56 $5,526 - $7,269	296 Added 2.03%	14,904 $362,000
Q4 2022 Feb 10, 2023	BUY	$17.24 - $23.95 $2,275 - $3,161	132 Added 0.91%	14,608 $312,000
Q4 2022 Feb 09, 2023	SELL	$17.24 - $23.95 $267,840 - $372,087	-15,536 Reduced 51.77%	14,476 $309,000
Q3 2022 Nov 02, 2022	SELL	$9.4 - $18.59 $140,454 - $277,771	-14,942 Reduced 33.24%	30,012 $538,000
Q2 2022 Aug 01, 2022	BUY	$9.12 - $18.9 $32,075 - $66,471	3,517 Added 8.49%	44,954 $432,000
Q1 2022 May 04, 2022	BUY	$12.15 - $16.83 $171,497 - $237,555	14,115 Added 51.66%	41,437 $574,000
Q4 2021 Feb 07, 2022	BUY	$13.83 - $18.78 $187,991 - $255,276	13,593 Added 99.01%	27,322 $457,000
Q3 2021 Nov 02, 2021	BUY	$7.07 - $17.5 $15,617 - $38,657	2,209 Added 19.18%	13,729 $223,000
Q2 2021 Aug 03, 2021	SELL	$5.69 - $7.17 $6,947 - $8,754	-1,221 Reduced 9.58%	11,520 $73,000
Q1 2021 May 04, 2021	SELL	$5.08 - $6.89 $2,352 - $3,190	-463 Reduced 3.51%	12,741 $79,000
Q4 2020 Feb 01, 2021	SELL	$5.65 - $7.66 $158 - $214	-28 Reduced 0.21%	13,204 $91,000
Q3 2020 Nov 09, 2020	BUY	$4.01 - $6.29 $4,034 - $6,327	1,006 Added 8.23%	13,232 $75,000
Q2 2020 Aug 07, 2020	BUY	$3.06 - $6.6 $17,396 - $37,521	5,685 Added 86.91%	12,226 $62,000
Q1 2020 May 04, 2020	SELL	$2.83 - $8.44 $933 - $2,785	-330 Reduced 4.8%	6,541 $23,000
Q4 2019 Feb 04, 2020	BUY	$0.93 - $8.58 $847 - $7,816	911 Added 15.29%	6,871 $46,000
Q3 2019 Nov 12, 2019	BUY	$1.09 - $1.29 $6,496 - $7,688	5,960 New	5,960 $7,000

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account